Your browser doesn't support javascript.
loading
ABSTRACT
The concept of theranostics, where individual patient-level biological information is used to choose the optimal therapy for that individual, has become more popular in the modern era of ‘personalised’ medicine. With the growth of theranostics, nuclear medicine as a specialty is uniquely poised to grow along with the ever-increasing number of concepts combining imaging and therapy. This special report summarises the status and growth of Theranostic Nuclear Medicine in Singapore.We will cover our experience with the use of radioiodine, radioiodinated metaiodobenzylguanidine, peptide receptor radionuclide therapy, prostate specific membrane antigen radioligand therapy, radium-223 and yttrium-90 selective internal radiation therapy.We also include a section on our radiopharmacy laboratory, crucial to our implementation of theranostic principles. Radionuclide theranostics has seen tremendous growth and we hope to be able to grow alongside to continue to serve the patients in Singapore and in the region.
Subject(s)
Key words
Full text: 1 Index: WPRIM Main subject: Prostate / Singapore / Yttrium / Radium / Receptors, Peptide / Hope / Theranostic Nanomedicine / Lutetium / Membranes / Nuclear Medicine Limits: Humans Country/Region as subject: Asia Language: En Journal: Korean Journal of Nuclear Medicine Year: 2019 Type: Article
Full text: 1 Index: WPRIM Main subject: Prostate / Singapore / Yttrium / Radium / Receptors, Peptide / Hope / Theranostic Nanomedicine / Lutetium / Membranes / Nuclear Medicine Limits: Humans Country/Region as subject: Asia Language: En Journal: Korean Journal of Nuclear Medicine Year: 2019 Type: Article